Cetuximab plus radiation improved OS in SCCHN

October 2008
Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p20
The article discusses a study which showed the efficacy of cetuximab plus radiation for treating patients with squamous cell carcinomas. The results of the study were presented by James A. Bonner, chairman of radiation oncology at the University of Alabama School of Medicine in Birmingham, at the 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. The overall survival rate for the patients in the combination arm and in the radiation group are indicated. The absolute survival rate benefit after five years is mentioned.


Related Articles

  • Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. SS Agarwala; E Cano; DE Heron; J Johnson; E Myers; V Sandulache; S Bahri; R Ferris; Y Wang; A Argiris // Annals of Oncology;Jul2007, Vol. 18 Issue 7, p1224 

    Background: Our goal was to evaluate long-term efficacy outcomes of patients with squamous cell carcinoma of the head and neck (SCCHN) treated with carboplatin, paclitaxel (Taxol) and radiotherapy. Patients and methods: We conducted a phase II trial in inoperable patients with locally advanced...

  • Cetuximab in head and neck cancer. Parikh, P. M.; Bhattacharyya, G. S.; Vora, A. // Indian Journal of Cancer;Apr-Jun2011, Vol. 48 Issue 2, p145 

    An introduction to the journal is presented in which the editor discusses the concomitant use of cetuximab with radiation therapy for patients with advanced squamous cell carcinoma of head and neck (SCCHN).

  • Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Mesía, R.; Rivera, F.; Kawecki, A.; Rottey, S.; Hitt, R.; Kienzer, H.; Cupissol, D.; De Raucourt, D.; Benasso, M.; Koralewski, P.; Delord, J.-P.; Bokemeyer, C.; Curran, D.; Gross, A.; Vermorken, J. B. // Annals of Oncology;Oct2010, Vol. 21 Issue 10, p1967 

    Background: A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). This analysis of the...

  • Cetuximab.  // Reactions Weekly;4/11/2009, Issue 1247/1248, p10 

    The article describes the cases of 10 men and 3 women with locally advanced head and neck squamous cell carcinoma who developed skin eruptions and mucositis during treatment with cetuximab and concomitant radiotherapy. The cetuximab treatment was finished by only 4 patients. Four patients...

  • Severe gastrointestinal bleeding in patients with locally advanced head and neck squamous cell carcinoma treated by concurrent radiotherapy and Cetuximab. Murakami, Naoya; Yoshimoto, Seiichi; Matsumoto, Fumihiko; Ueno, Takao; Ito, Yoshinori; Watanabe, Satoru; Kobayashi, Kazuma; Harada, Ken; Kitaguchi, Mayuka; Sekii, Shuhei; Takahashi, Kana; Yoshio, Kotaro; Inaba, Koji; Morota, Madoka; Sumi, Minako; Saito, Yutaka; Itami, Jun // Journal of Cancer Research & Clinical Oncology;Jan2015, Vol. 141 Issue 1, p177 

    Purpose: Concurrent administration of Cetuximab with radiotherapy (Cetuximab-radiation) has been accepted as an alternative option for locally advanced head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to retrospectively compare complications of Cetuximab-radiation...

  • Incidence of mucositis in patients with head and neck squamous cell carcinoma treated with radiotherapy plus cetuximab: a pilot study. Bodard, Anne-Gaëlle; Hrifach, Abdelbaste; Salino, Samuel; Fabris, Matthieu; Desoutter, Aline; Pommier, Pascal; Fayette, Jérôme // Médecine Buccale Chirurgie Buccale;2012, Vol. 18 Issue 3, p181 

    Objectives: Cetuximab-induced mucositis has been poorly reported in the literature. The aim of this pilot study was to determine the severity and incidence of oral mucositis in patients treated with radiotherapy plus cetuximab. Materials and methods: Patients treated for a head and neck squamous...

  • Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Schmitz, S.; Hamoir, M.; Reychler, H.; Magremanne, M.; Weynand, B.; Lhommel, R.; Hanin, F.-X.; Duprez, T.; Michoux, N.; Rommel, D.; Lonneux, M.; Cappoen, N.; Gillain, A.; Machiels, J.-P. // Annals of Oncology;Sep2013, Vol. 24 Issue 9, p2261 

    Background To investigate the safety and activity of cetuximab in the pre-operative treatment of squamous cell carcinoma of the head and neck (SCCHN). Patients and methods Cetuximab was administered for 2 weeks before surgery to 33 treatment-naïve patients selected for primary surgical...

  • Surgery and cetuximab most effectively treated very high-risk CSCC.  // Hem/Onc Today;11/10/2013, Vol. 14 Issue 21, p27 

    The article discusses a research paper on the efficacy of surgery and cetuximab in treating high-risk cutaneous squamous cell carcinoma, which references a study by K. O'Bryan et al., published in a 2013 issue of the "Journal of the American Academy of Dermatology."

  • Adding cetuximab to RT: ahead for cost effectiveness in Taiwan.  // PharmacoEconomics & Outcomes News;10/29/2011, Issue 640, p3 

    The article focuses on a study in Taiwan which showed that high-dose radiotherapy (RT) combined with cetuximab (Erbitux) chemotherapy is more cost effective in treating locally-advanced squamous cell carcinoma of the head and neck than when using radiotherapy alone.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics